Recently, I talked about Moderna being an attractive investment. Moderna is one of the companies that’s leading in the race to develop a vaccine against COVID-19.
This morning, Pfizer has delivered good news related to the company’s trial results.
Vaccine candidate was found to be more than 90% effective in preventing COVID-19 in participants without evidence of prior SARS-CoV-2 infection in the first interim efficacy analysis. Study enrolled 43,538 participants, with 42% having diverse backgrounds, and no serious safety concerns have been observed; Safety and additional efficacy data continue to be collected
This is indeed good news as a second wave of coronavirus infections rage across the United States and Europe.
Pfizer CEO has also said that he is willing to take the vaccine first to demonstrate the safety.
From a stock price perspective, Pfizer has delivered negative returns of 3% in the last one year. However, with the news, the stock is higher by 8% in early morning trade.
If the positive developments continue and if Pfizer is able to deliver a vaccine against the COVID-19, I expect the positive stock momentum to continue into 2021.
It’s worth noting that following the positive results of the Phase 3 trials, the United Kingdom is expecting to receive 10 million doses of the vaccine by the end of the year.
I am expecting more such commitments from governments globally and this will be positive news for PFE stock. At a forward P/E of 12.6, Pfizer stock is attractive for medium to long-term investors.
I believe that investors who are looking at pharmaceutical companies that are likely to deliver a vaccine against COVID-19 can consider one of the following stocks.
- Moderna
- Pfizer
- AstraZeneca
For Moderna, the Phase 3 trials are expected to begin in 2021. Moderna has also secured commitments from United States, European Commission, Japan and Qatar for buying the vaccine.
Similarly, AstraZeneca is also close to delivering a vaccine. As a matter of fact, the company will deliver 4 million doses of the vaccine to the U.K. government by the end of this year.
AstraZeneca also has a global supply chain that will enable production of 3 billion doses of the vaccine once regulatory approvals are achieved.
Posted Using LeoFinance Beta
Don´t celebrate too early. The "positive" news come from 91 cases of Covid-19 developed in 44000 test subjects. No safety follow up data so far available.
Only due to the plandemic state it would be ethic to license a drug based on so few data. There could be thousands of vaccination victims in a few years (read more about it in my post on the topic here.
I agree with your view. I am cautiously optimistic.
However, I am looking from the perspective of stock price action. Governments will allow multiple vaccines in the market and companies will make billions of dollars.
Posted Using LeoFinance Beta
I wouldn't take a vaccine for covid even if threatened by gun. There are so many vaccines related illness in both children and adults that it is irrelevant to consider such vaccines safe. Pharmaceutical industry is a highly profitable one and that's why all the buzz around covid. Specialists however claim that you can't have a proper vaccine in such a quick time. It's all about money and they seem to prevail in anything on this planet.
Posted Using LeoFinance Beta
100% agree.
Congratulations @fhk007! You have completed the following achievement on the Hive blockchain and have been rewarded with new badge(s) :
You can view your badges on your board and compare yourself to others in the Ranking
If you no longer want to receive notifications, reply to this comment with the word
STOPI hate to say it but they have had a vaccine the whole time. I'm 99% sure that Gates foundation already owns a patent on the Anti along with the patent that he already owns to the COVID-19 virus. Yes, I said that correctly. It's all over the net. Along with a lot of other Juicy tidbits. See I think it was all planned and according to the conspiracy theorists, there's a lot going on behind the scenes.
Posted Using LeoFinance Beta